Gregory Tietjen, PhD
Assistant Professor Adjunct of Surgery (Transplant)About
Research
Academic Achievements & Community Involvement
News & Links
Media
- The Tietjen lab employs molecularly targeted nanoparticle-based drug carriers as a mechanism to control the cellular and intra-organ distribution of encapsulated therapeutics. We are particularly focused on delivery of immunomodulatory drugs to vascular endothelium.
- Ex vivo organ perfusion has emerged as a valuable clinical strategy to assess and potentially revive marginal organs in solid organ transplantation. These periods of ex vivo perfusion provide an ideal window to deliver therapeutics directly to the graft without concern for unwanted system effects. Working in collaboration with leading transplant clinicians at the University of Cambridge, we have been adapting our vascular targeted nanoparticles for use during ex vivo normothermic perfusion of kidney. In on going work, we are looking to integrate a suite of biophysical tools to allow for realtime, 3D evaluation of nanoparticle accumulation during organ perfusion. Image courtesy of Dr. Sarah Hosgood - University of Cambridge.
News
- December 18, 2022
Yale Insights in Cardiovascular Medicine: 2022
- February 27, 2022
Stendahl awarded K08 career development award from NHLBI
- March 24, 2021
How COVID-19 is transforming the ways we work
- July 06, 2020Source: YaleNews
Yale, Cambridge Pioneer New Way to Make Kidneys Safe for Transplant